The FDA has approved Genentech’s innovator rituximab (Rituxan) for the treatment of adults with moderate to severe pemphigus vulgaris (PV). This expanded indication makes the drug the first biologic approved for the treatment of PV, a rare autoimmune disease that affects the skin and mucous membranes with progressive blistering.
The FDA has approved Genentech’s innovator rituximab (Rituxan) for the treatment of adults with moderate to severe pemphigus vulgaris (PV). This expanded indication makes the drug the first biologic approved for the treatment of PV, a rare autoimmune disease that affects the skin and mucous membranes with progressive blistering. The life-threatening condition affects approximately 30,000 to 40,000 people in the United States.
The FDA had previously granted the biologic priority review, breakthrough therapy designation, and Orphan Drug Designation for the treatment of PV. In total, the reference product is now licensed to treat 6 diseases: non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and PV.
“Today’s decision by the FDA provides the first approved treatment option in more than 60 years for patients with [PV], a potentially life-threatening disease,” said Sandra Horning, MD, chief medical office and head of global product development at Genentech, in a statement.
The approval was based on data from a randomized, controlled, open-label, multicenter study—the Ritux 3 trial—conducted in France. The study compared the EU-approved rituximab product plus short-term corticosteroids (collectively, the Ritux 3 regimen) to corticosteroids alone as a first-line treatment in patients with moderate to severe pemphigus.
The primary endpoint of the study was complete remission (defined as complete epithelialization and absence of new and/or established lesions) at 24 months without the use of steroids for 2 or more months, and was achieved by 90% of patients treated with the Ritux 3 regimen versus 28% of patients treated with corticosteroids alone.
Based on the results of the trial, the International Bullous Disease Consensus Group developed international diagnostic and management guidelines for PV. A preliminary survey based on the European Dermatology Forum and the European Academy of Dermatology and Venereology guidelines was sent to a panel of international experts to determine the level of consensus in regard to the treatment of PV with rituximab and short-term corticosteroids.
After the results were initially discussed during the annual American Academy of Dermatology conference, a second survey was sent out to achieve greater international consensus. In total, 39 experts participated in the first round of the survey, while 54 experts from 21 different countries participated in the second round. The international consensus was to recommend reference rituximab and corticosteroids as first-line therapy options for moderate to severe PV.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships
May 29th 2025The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.
British Columbia’s Biosimilar Policy Shows No Impact on Hospital Visits
May 28th 2025Despite a dramatic shift toward biosimilar use following British Columbia’s policy, researchers found no rise in hospital visits or complications, underscoring the real-world reliability of etanercept biosimilars in managing inflammatory arthritis.